ABEO Abeona Therapeutics Inc.

2.29
+0.2  (+10%)
Previous Close 2.09
Open 2.19
Price To Book 1.07
Market Cap 191,494,689
Shares 83,622,135
Volume 1,456,560
Short Ratio
Av. Daily Volume 1,722,539
Stock charts supplied by TradingView

NewsSee all news

  1. ABEONA THERAPEUTICS INC. General Corporate Statement (Form8) (0001493152-20-005895)

  2. Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic

    NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staff of providers are now

  3. Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17, 2020 (GLOBE

  4. Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates

    On track to treat first RDEB patient in pivotal Phase 3 VIITAL™ study of EB-101 in Q1 2020 Positive interim data from MPS IIIA and MPS IIIB programs presented at WORLDSymposium™; Completion of cohort 2 and first patient

  5. Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    NEW YORK and CLEVELAND, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 presentation at WORLDSymposium February 12, 2020 noted trial has been well-tolerated to date, with no treatment-related severe adverse events.
ABO-101
Sanfilippo syndrome type B (MPS IIIB)
Phase 3 initiation of dosing announced March 17, 2020.
EB-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 presentation at WORLDSymposium February 12, 2020 noted trial has been well-tolerated. 3/3 patients in high-dose cohort 3 showed improved neurocognitive skills 18 months to two years post treatment.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)
Phase 1/2 trial planned.
ABO-202
CLN1 disease (Infantile Batten disease)

Latest News

  1. ABEONA THERAPEUTICS INC. General Corporate Statement (Form8) (0001493152-20-005895)

  2. Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic

    NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staff of providers are now

  3. Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17, 2020 (GLOBE

  4. Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates

    On track to treat first RDEB patient in pivotal Phase 3 VIITAL™ study of EB-101 in Q1 2020 Positive interim data from MPS IIIA and MPS IIIB programs presented at WORLDSymposium™; Completion of cohort 2 and first patient

  5. Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    NEW YORK and CLEVELAND, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer,

  6. Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™

    Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment Dose-dependent and sustained reductions in disease-specific biomarkers denotes clear biologic effects of ABO-102

  7. Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa

    NEW YORK and CLEVELAND, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the first World Congress on

  8. Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids

    NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office

  9. Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in Cleveland NEW YORK and

  10. Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten public offering,

  11. Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants

    NEW YORK and CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its public offering of 26,982,945

  12. Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA

    NEW YORK and CLEVELAND, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that the European Medicines Agency (EMA) has granted

  13. Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants

    NEW YORK and CLEVELAND, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and sell shares of its

  14. Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    FDA removes clinical hold; Company may proceed with VIITAL™ study Company expects to initiate study in the first quarter of 2020 Primary endpoint confirmed as proportion of wounds with greater than 50% healing at 3

  15. Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates

    Submitted additional EB-101 transport stability data to FDA in response to Clinical Hold Letter; CMC clearance for pivotal VIITALTM Phase 3 trial anticipated in Q4 2019Publication of positive long-term data for EB-101

  16. Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress

    NEW YORK and CLEVELAND, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced the presentations of data from the Transpher A

  17. Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    Sustained wound healing and favorable safety profile observed at three years post-treatment Durable wound healing in large, disabling, chronic wounds EB-101 associated with long-term molecular expression of Type VII

  18. Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa

    Company to provide additional transport stability data points in response to FDA Clinical Hold LetterCMC clearance for VIITAL™ trial anticipated in Q4 2019Investor conference call today, Monday, September 23 at 09:30

  19. Abeona Therapeutics Announces Strategic Review

    NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies LLC as its financial